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Regulatory T cells (Tregs), either thymic derived or
peripherally induced, suppress a variety of physiolog-
ical and pathological immune responses, and the
absence of this cell subset has been shown to result in
severe systemic autoimmunity. Since their acceptance
almost two decades ago, intensive research aiming to
characterize the phenotype, to elucidate the suppres-
sive activity, and to decipher the migratory behavior of
Tregs has been performed. A substantial number of
studies, however, focused on understanding whether
defects in Treg numbers and function contribute to
the development and progression of inflammatory,
autoimmune, and malignant disorders, and how
Treg numbers/function might be modulated to treat
patients with autoimmune diseases or cancer. In the
skin, an organ that is constantly exposed to the
environment, Tregs are known to be critically involved
not only in the maintenance of skin homeostasis
but also in the regulation of cutaneous immune
responses. In this review, we present an overview on
recent data concerning Treg development and expan-
sion, the molecular mechanisms underlying their
immunosuppressive activity, and the modulation of
Treg function. Furthermore, we discuss the role of
Tregs in cutaneous inflammatory and autoimmune
disorders.
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INTRODUCTION
Immune responses need to be controlled and be turned down
after completion, as without downregulation immune reac-
tions are at high risk to become pathologic. In the past,
CD4þCD25þ regulatory T cells (Tregs) have been shown to
have a crucial role in dampening immune responses against
pathogens and in maintaining immunological self-tolerance
and immune homeostasis. In addition, Tregs represent an
important cellular mechanism by which tumors evade
immunosurveillance (Sakaguchi, 2005; Shevach, 2009).
Hence, as key regulators of immune responses, Tregs have
to be considered as therapeutic targets. Manipulation of
numbers and/or suppressive activity of Tregs was shown to be
useful in the treatment of various diseases, including
autoimmune disorders, allograft rejection, graft-versus-host
disease, and cancer (Shevach, 2009; Chen and Oppenheim,
2011). Accordingly, depletion of Tregs led to severe systemic
autoimmunity and provoked immune responses to commen-
sal bacteria in the intestine, causing inflammatory bowel
disease (Singh et al., 2001; Ohkura et al., 2011), but on the
other hand resulted in efficient antitumoral or antimicrobial
immunity (Belkaid and Rouse, 2005). Moreover, antigen-
specific expansion of Tregs was used to treat allergic diseases
and establish immunological tolerance to organ grafts, as
well as prevent graft-versus-host disease after bone marrow
transplantation (Ohkura et al., 2011).
Naturally occurring Tregs constitute 5–10% of total CD4þ
T cells in mice and healthy humans, are produced in the
thymus as a distinct mature subpopulation of T cells, and
are characterized by the expression of the forkhead family
transcription factor, Foxp3, as well as characteristic cell-
surface markers, including a variety of co-stimulatory and
co-inhibitory molecules (CD28, cytotoxic T lymphocyte anti-
gen 4 (CTLA-4), inducible co-stimulator, etc.), tumor necrosis
factor (TNF)/TNF receptor family members (RANKL, GITR,
OX40, 4-1BB, etc.), chemokine and Toll-like receptors (CCR2,
CCR4, CCR5, CCR6, CCR7, CCR8, CXCR3, CXCR4, TLR1,
TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, and TLR9), and a
variety of immunosuppressive cytokines (IL-10, transforming
growth factor (TGF)-b, IL-35, etc.; reviewed in Lu and
Rudensky, 2009; Shevach, 2009; Campbell and Koch, 2011;
Chen and Oppenheim, 2011; Ohkura et al., 2011). In addition
to naturally occurring thymic-derived CD4þCD25þFoxp3þ
Tregs, Foxp3 T cells with suppressive activity, including
IL-10-secreting Tr1 cells or TGF-b-induced Th3 cells, have
been described (Mills and McGuirk, 2004; Wu et al., 2007),
which are thought to have a significant role in the mainte-
nance of peripheral tolerance. However, at present, little is
known about the contribution of Foxp3 Tregs to ordinary
immune responses and to sustaining self-tolerance. Thus,
this review will focus on Foxp3þ Tregs and discuss the
characteristics and migratory behavior of this cell subset.
COMPLEX CONTROL OF FOXP3 EXPRESSION
Initially, the Foxp3 gene was identified in Scurfy mice,
and mutations in the Foxp3 locus were associated with
X-linked autoimmune disease, dysregulated T-cell function,
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hyperactivation of CD4þ T cells, and overproduction of pro-
inflammatory cytokines (Brunkow et al., 2001). In humans,
mutations in the FOXP3 gene have been linked to Treg
deficiency, causing a severe systemic autoimmune disease
called immune dysregulation, polyendocrinopathy, enterop-
athy, X-linked syndrome (Bennett et al., 2001; Gambineri
et al., 2008). In mice and humans, Foxp3 has a crucial role
for the function of Treg, as ectopic retroviral transduction
of the Foxp3 gene into conventional CD4þCD25 T cells
converts them to CD4þCD25þ Tregs able to suppress the
proliferation of effector T cells in vitro and to inhibit the
development and progression of systemic T-cell–mediated
autoimmune disorders in vivo (Fontenot et al., 2003; Hori
et al., 2003; Loser et al., 2005a). Moreover, after retroviral
Foxp3 transduction, CD4þ T cells upregulated the expression
of Treg-associated markers such as CTLA-4, CD25, and
neuropilin-1 (Loser et al., 2005a). The functional and
phenotypic hallmarks of CD4þ T cells ectopically expressing
Foxp3 are similar to those observed in naturally occurring
thymic-derived Tregs, indicating that Foxp3 is indeed a key
regulator of Treg development and Treg function. However,
in humans, FOXP3 can be induced upon activation in
conventional CD4þ T cells, which do not show any
suppressive activity, indicating differences in the regulation
of Foxp3 expression between mice and humans, and,
furthermore, suggesting that FOXP3 is less reliable in defining
human Tregs than mouse Tregs (Allan et al., 2007; Tran et al.,
2007; Miyara et al., 2009).
During Treg development in the thymus, Foxp3 expression
is controlled by signaling pathways, including TCR signaling,
co-stimulation, cytokine production, and binding of various
transcriptional activators to the Foxp3 promoter (Kim and
Leonard, 2007; Samon et al., 2008; Tone et al., 2008; Kim
et al., 2009). After TCR engagement with self-peptide/major
histocompatibility complex ligands, Foxp3 gene expression is
initiated by the binding of the transcription factors, activator
protein 1, nuclear factor of activated T cells, cyclic AMP-
responsive element–binding protein, and activating transcrip-
tion factor, to the promoter region or to an intronic Foxp3
sequence proposed to serve as an enhancer (Mantel et al.,
2006; Kim and Leonard, 2007; Lu and Rudensky, 2009).
Besides TCR signaling and transcription factor binding,
CD28/B7-1- or CD28/B7-2-mediated co-stimulation is re-
quired to stabilize Foxp3 expression, as the absence of either
CD28 or its ligands B7-1 and B7-2 results in reduced numbers
of Foxp3þ thymocytes and peripheral Tregs (Loser et al.,
2005b; Tai et al., 2005). Moreover, in vitro studies have
shown that increased activation of the Akt (acutely transform-
ing retrovirus AKT8 in rodent T-cell lymphoma)–mammalian
target of rapamycin pathway (a main target of CD28
signaling) caused impaired Foxp3 expression and thymic
Treg generation (Haxhinasto et al., 2008). In contrast,
inhibition of phosphatidylinositol-3-kinase, and thereby of
Akt activation, induced Foxp3, and mice with an inactive
phosphatidylinositol-3-kinase isoform showed significantly
increased numbers of thymic Treg (Patton et al., 2006; Sauer
et al., 2008). TCR and co-stimulatory signals seemed
insufficient to induce Foxp3 expression and functional Treg
in the thymus, as mice lacking IL-2 or the IL-2 receptor
developed a severe lymphoproliferative disease and exhib-
ited significantly reduced numbers of Foxp3þ Tregs (Furtado
et al., 2002; Malek et al., 2002, 2008; Fontenot et al., 2005;
Burchill et al., 2007; Vang et al., 2008), suggesting a two-step
model for Treg generation in the thymus. First, a TCR signal in
combination with the interaction of co-stimulatory molecules
results in the upregulation of CD25 and the development of a
Treg precursor, which in a second step receives an IL-2 signal
leading to the induction of Foxp3 expression. Of note, IL-2-
mediated induction of Foxp3 in Tregs requires the activity
of Jak 1 and 3 (JAK1/JAK3) and the signal transducer and
activator of transcription 5 (STAT5; Burchill et al., 2008; Lio
and Hsieh, 2008; Lu and Rudensky, 2009), as Jak3-deficient
mouse mutants lack Foxp3 expression completely and
conditional knockout mice lacking STAT5 in thymocytes
show strongly reduced numbers of Foxp3þ cells, whereas
overexpression of a constitutively active form of STAT5
results in the expansion of Treg (Burchill et al., 2007, 2008;
Yao et al., 2007).
Besides IL-2, TGF-b was demonstrated to be important for
Treg generation. Although the contribution of TGF-b to
thymic development of Tregs is still discussed intensely, TGF-
b is central for the homeostasis of naturally occurring Tregs,
as well as for Foxp3 upregulation and induction of
suppressive activity in conventional CD4þ T cells (Chen
et al., 2003; Zheng et al., 2004; Marie et al., 2005; Liu et al.,
2008). However, this acquired Treg phenotype is unstable, as
most of the TGF-b-induced Tregs lose Foxp3 expression and
suppressor function in the absence of the cytokine, indicating
that stable Foxp3 expression is a prerequisite for the
maintenance of suppressive activity in Tregs (Floess et al.,
2007; Huehn et al., 2009). More recently, epigenetic
regulation was identified as a crucial factor for controlling
stable Foxp3 expression by modulating the accessibility of
the Foxp3 promoter for binding of transcription factors
(Huehn et al., 2009). In particular, the methylation of three
distinct and highly conserved CpG motifs in the human and
mouse Foxp3 promoter results in the condensation of
chromatin, whereas demethylation of these CpG motifs leads
to the relaxation of chromatin and thereby to an increased
transcriptional accessibility of the Foxp3 gene (Huehn et al.,
2009). In naturally occurring thymic-derived Tregs, the CpG
motifs of the Foxp3 promoter are demethylated almost
completely, whereas they are methylated in resting conven-
tional CD4þ T cells (Kim and Leonard, 2007; Janson et al.,
2008), indicating an amplified Foxp3 transcription in Tregs.
Interestingly, demethylation of the Foxp3 promoter was found
to be increased in conventional CD4þ T cells after TGF-b
treatment, whereas neutralizing TGF-b upregulated the
methylation of CpG motifs in the Foxp3 promoter, and thus
completely abrogated the transient expression of Foxp3 (Tran
et al., 2007). Together, these data suggest a role for DNA
demethylation in the regulation of stable Foxp3 expression in
thymic-derived natural Tregs. In contrast, T cells that express
Foxp3 only transiently, such as TGF-b–induced Tregs, are
characterized by a methylated Foxp3 promoter (Baron et al.,
2007; Floess et al., 2007; Polansky et al., 2008).
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MECHANISMS OF TREG-MEDIATED SUPPRESSION
Tregs inhibit the differentiation, activation, proliferation,
cytokine secretion, or migration of conventional T cells.
However, despite the increasing evidence of Tregs’ involve-
ment in immune regulation, relatively little is known about
the molecular mechanisms underlying Treg-mediated sup-
pression. By performing in vitro suppression assays or by
using various mouse models and intravital microscopy, many
mechanisms for Treg-mediated suppressor function have
been suggested (Sakaguchi et al., 2009; Shevach, 2009). In
particular, in vitro assays revealed a cell contact–dependent
mechanism, as Tregs separated from the responder cells by a
semipermeable membrane were unable to inhibit effector
cell proliferation, and, moreover, culture supernatants from
antigen-stimulated Tregs failed to exhibit suppressive activity
(Takahashi et al., 1998; Thornton and Shevach, 1998). When
analyzing the cell contact–dependent suppressor mechanism
in more detail, Grohmann et al. (2002) could show that Tregs
induce the expression of indoleamine 2,3-dioxygenase in
dendritic cells, a potent regulatory molecule mediating the
catabolism of the amino acid tryptophan into the pro-
apoptotic kynurenine, which is particularly toxic to T cells.
Notably, this process was dependent on CTLA-4, a surface
marker constitutively expressed on Tregs, as blocking CTLA-4
signaling by anti-CTLA-4 reversed the Treg-mediated suppres-
sion of effector T-cell proliferation (Thornton et al., 2004).
To strengthen the relevance of CTLA-4 for the suppressive
activity of Treg, Wing et al. (2008) selectively deleted CTLA-4
and demonstrated that mutant mice with a deletion of CTLA-4
expression in Tregs developed a systemic autoimmune disease
similar to that observed in Scurfy mice. Cellular analysis
revealed that the CTLA-4 deficiency altered neither the
thymic development nor the peripheral homeostasis of Tregs
but downregulated their suppressive activity. Thus, CTLA-4
deficiency in Tregs alone was sufficient to abrogate its
suppressor function (Wing et al., 2008; Shevach, 2009).
Another suppressive mechanism used by Tregs to inhibit
effector T-cell differentiation and proliferation is the catalytic
inactivation of adenosine triphosphate (ATP) by CD39, which
represents the dominant ectoenzyme in the immune system,
hydrolyzing tissue-destructive ATP to AMP (Borsellino et al.,
2007). Notably, as retroviral transduction of CD4þCD25
conventional T cells with Foxp3 induced the expression of
CD39, and CD39-deficient Tregs were dysfunctional, pro-
liferated in response to anti-CD3/anti-CD28 stimulation, and
failed to suppress the proliferation of responder T cells, the
investigators concluded that CD39, and thus the degradation
of ATP to AMP, might be crucial for the Treg function
(Shevach, 2009). These observations were proven in a
cutaneous contact allergy model, showing that Tregs expres-
sing CD39 efficiently suppressed the ear swelling response in
mice upon challenge with an obligate contact allergen,
whereas CD39-deficient Tregs were not suppressive (Ring
et al., 2009). Interestingly, in allergen-challenged ears CD39-
expressing Tregs inhibited the adhesion of activated effector
T cells to inflamed endothelium by downregulating the
expression of E- and P-selectin on vascular endothelial cells
(Ring et al., 2009, 2010), blocking ear swelling and erythema.
In another approach, several groups used DNA microarray
analyses to elucidate the molecular mechanisms of Treg
suppressive activity. Comparing the gene expression profiles
of Tregs with those of naive or recently activated T cells
revealed a substantial number of genes. Among these are TNF
family members such as the glucocorticoid-induced TNF
receptor–related protein (GITR, CD357), OX40 (CD134), and
4-1BB (CD137; McHugh et al., 2002; Shimizu et al., 2002;
Valzasina et al., 2005; So et al., 2008), which were
controversially presented as negative regulators of Treg-
mediated suppression. All three markers are constitutively
expressed on Tregs but are also upregulated on Foxp3
effector T cells upon antigen stimulation, and it has been
claimed that engagement of GITR, OX40, or 4-1BB reverses
the suppressor function of Tregs (Stephens et al., 2004;
Valzasina et al., 2005; So et al., 2008). Accordingly,
preincubation of Tregs with an agonistic anti-OX40 antibody,
e.g., resulted in the loss of suppressor function in an in vivo
mouse model of graft-versus-host disease and, moreover, led
to increased antitumoral immunity, as evidenced by com-
plete rejection of established tumors (Piconese et al., 2008).
In addition, gene expression studies of Tregs compared with
naive or effector CD4þ T cells enabled the identification of
suppressive humoral factors such as the galactoside-binding
proteins, galectin-1 and galectin-10, or the immunosuppres-
sive cytokine IL-35, which is a member of the IL-12 family
and a heterodimer comprising Ebi3 and IL-12a/p35 (Collison
et al., 2007; Garin et al., 2007; Kubach et al., 2007; Tang and
Bluestone, 2008; Vignali et al., 2008). Interestingly, antibody-
mediated blockade of galectin-1 or galectin-10 reduced
significantly the inhibitory effects of human and mouse Tregs;
moreover, Tregs from galectin-1–deficient mouse mutants
showed a reduced suppressive activity compared with Tregs
from wild-type controls, suggesting that galectins are
essential for Treg function (Garin et al., 2007; Kubach
et al., 2007). IL-35 is constitutively expressed in Tregs, and
it has been demonstrated that ectopic expression of IL-35
confers suppressive activity to naive CD4þ T cells. Further-
more, treatment of naive human or mouse T cells with IL-35
induced a regulatory phenotype, whereas recombinant IL-35
suppressed T-cell proliferation in vitro, as well as in vivo,
suggesting IL-35 as a cytokine required for maximal
suppressive activity in Tregs (Collison et al., 2007, 2010).
Together, these findings indicate that several mechanisms,
including cell contact–dependent mechanisms and those
mediated by soluble factors, are involved in Treg suppressor
function. However, most of the suppressive mechanisms have
been elucidated in vitro. Further in vivo studies might be
required to decipher whether these mechanisms also apply
in vivo.
MODULATION OF TREG FUNCTION
As Tregs have a crucial role in maintaining the balance of
autoimmunity and immunosuppression, the numbers and the
activity or tissue-specific migration of this cell population
must be controlled tightly. In this context, signaling between
RANK (CD265)-expressing epidermal antigen-presenting
Langerhans cells (LCs) and RANKL (CD254)-overexpressing
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keratinocytes in K14-RANKL transgenic mice has been shown
to result in the increased capacity of LC to induce the
proliferation of Tregs. This phenomenon is possibly mediated
by the elevated expression of DEC205 (CD205) and CD86, as
well as increased IL-10 secretion, factors that have previously
been associated with the expansion of Tregs via antigen-
presenting cells (Mahnke et al., 2003; Loser et al., 2006;
Loser and Beissert, 2009). In support of this suggestion,
depleting LC from K14-RANKL transgenic epidermis caused a
substantial reduction of Treg numbers in regional lymph
nodes, indicating that antigen-presenting cells stimulated
via RANK–RANKL interactions can maintain peripheral
numbers of Tregs (Loser et al., 2006). At least in skin, one
of the regulators of RANKL expression is active vitamin D3,
which is enzymatically produced from an inactive precursor
by LC upon inflammation or exposure to environmental
factors such as UV light (Kim et al., 2007; Sigmundsdottir
et al., 2007; Sigmundsdottir and Butcher, 2008). Notably,
active vitamin D3 has been demonstrated to enhance
Treg function (Gorman et al., 2007), suggesting that active
vitamin D3 upregulates RANKL and, subsequently, LC
stimulated via RANK–RANKL signaling migrate to regional
lymph where they induce the Treg proliferation (Loser and
Beissert, 2009).
After expansion in secondary lymphoid organs, the activity
of Tregs and their homeostatic and migratory properties are
regulated precisely. In particular, the expression of specific
adhesion molecules and tissue-specific chemokine receptors
are critical for targeting Tregs to both lymphoid and non-
lymphoid tertiary organs. Accordingly, in addition to their
well-known presence in secondary lymphoid tissues, Tregs
are detectable in non-lymphoid tissues even in the absence of
inflammation (Sather et al., 2007; Campbell and Koch, 2011).
Recently, gene expression analyses revealed the relevance of
tissue homing receptors for the appropriate localization and
function of Tregs. Expression of the alphaE integrin (CD103),
as well as the chemokine receptor CC-chemokine receptor 4
(CCR4), and the ability to produce E- and P-selectin ligands
by the activity of a-(1,3)-fucosyltransferase VII are important
for Treg migration toward the skin (Campbell and Koch,
2011). Consequently, deletion of CD103, CCR4, or a-(1,3)-
fucosyltransferase VII resulted in the development of cuta-
neous autoimmune diseases (Sather et al., 2007; Dudda et al.,
2008; Freyschmidt et al., 2010). Besides their constitutive
circulation through tertiary tissues such as skin, Treg
migration to non-lymphoid organs is increased significantly
during inflammation. However, the expression of inflamma-
tion-induced homing receptors on Tregs is largely dependent
on the type of tissue and the kind of inflammation (Campbell
and Koch, 2011). For example, Th17-mediated inflammation,
such as that observed in experimental autoimmune encepha-
lomyelitis or psoriasis, is characterized by high levels of the
CCR6 ligand CCL20 in inflammatory lesions; thus, CCR6
expression on Tregs is essential for optimal recruitment to
sites of Th17-mediated inflammation (Yamazaki et al., 2008;
Loser, unpublished observation). In contrast, Th1-mediated
inflammation characterized by elevated IFN-g concentrations
promotes the expression of the CXC-chemokine receptor 3
(CXCR3) ligands, CXCL9, CXCL10, and CXCL11, in inflam-
matory lesions. Hence, in a mouse model of Th1-driven,
concanavalin A-induced hepatiis, CXCR3-expressing Tregs
migrate to inflamed liver tissue (Santodomingo-Garzon et al.,
2009). Apart from these examples, a variety of other tissue
homing receptors have been identified on Tregs, including
CCR2, CCR4, CCR9, CCR10, CXCR4, CXCR6, aEb7 integrin,
a4b7 integrin, and P- and E-selectin ligands (Campbell and
Koch, 2011; Loser, unpublished observations), suggesting
that Tregs might use a combination of homing receptors to
control their migration to tertiary tissues during inflammation.
Having migrated to inflammatory tissues, Treg suppressor
function and Treg survival are controlled by cytokines and a
variety of small molecules. Influencing Treg development,
viability or activity is of therapeutic interest, and therefore the
role of various cytokines and small molecules on Treg
suppressive activity has been investigated in detail. As
mentioned previously, binding of IL-2 to the IL-2 receptor
controls Foxp3 expression via STAT5. Thus, IL-2 was shown
to upregulate the proliferation of Tregs in cancer patients, and
blocking IL-2 signaling led to reduced numbers of Tregs in
clinical responders (Wei et al., 2007). Moreover, administra-
tion of IL-2 stimulated the CXCR4 expression on Tregs and,
thus, enabled Treg migration toward the CXCR4 ligand
CXCL12 in a tumor microenvironment; this may therefore
result in Treg accumulation in tumors (Ohkura et al., 2011).
Rapamycin, an immunosuppressive drug inhibiting IL-2
signaling and thereby blocking the activation of T and B
cells, has been demonstrated to promote the expansion of
Tregs by inhibition of effector T-cell proliferation (Battaglia
et al., 2006). Accordingly, treatment of non-obese diabetic
mice with rapamycin prevents the induction of Type 1
diabetes, and furthermore expands naturally occurring
Foxp3þ Tregs. In addition, in vitro treatment of Tregs from
Type 1 diabetes patients with rapamycin upregulated their
suppressive activity (Monti et al., 2008), suggesting that
rapamycin might promote the generation/expansion of Tregs
in vitro and in vivo. More recently, the sphingosine
1-phosphate receptor agonist FTY720, which is normally
used to prevent graft rejection during organ transplantation,
was shown to increase the suppressive activity of Tregs
in vitro, and furthermore to upregulate the expression of
Foxp3 and the secretion of anti-inflammatory cytokines such
as IL-10 and TGF-b (Zhou et al., 2009). Hence, FTY720 might
be suitable as a therapeutic alternative for the treatment of
autoimmune disorders. Besides these rather indirect mecha-
nisms to modulate Treg function using immunosuppressive
drugs, such as retinoic acid, rapamycin, or FTY720, Treg
activity can be controlled directly by targeting Treg-asso-
ciated molecules with monoclonal antibodies. Accordingly,
in mouse experiments, the in vivo administration of anti-
GITR-, anti-OX40-, or anti-Folate Receptor 4 antibodies
reduced significantly the numbers of peripheral Tregs,
resulting in increased antitumoral immunity (Ko et al.,
2005; Yamaguchi et al., 2007; Piconese et al., 2008). Similar
observations were made in human patients with metastatic
melanoma: the administration of the CD25-directed immuno-
toxin RFT5-SMPT-dgA induced a transient reduction in
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peripheral Treg numbers in vivo (Powell et al., 2008).
Together, different mechanisms are known to control the
homeostasis, suppressor function, and migratory properties of
Tregs, including antibodies or small molecules interfering
with the suppressive activity of Tregs; active vitamin D3 and
RANKL, involved in regulating Treg expansion; and chemo-
kine receptors or particular integrins functioning as homing
receptors to modulate Treg migration toward inflammatory
tertiary tissues.
TREGS IN INFLAMMATORY SKIN DISORDERS
Tregs exist in almost all tertiary tissues, and a particularly high
number of Tregs has been detected in skin (Dudda et al.,
2008; Tomura et al., 2010). To analyze the function of
cutaneous Tregs, Dudda et al., 2008) reconstituted Foxp3-
deficient Scurfy mice with Tregs lacking the ability to migrate
to the skin, which resulted in the rapid development of
cutaneous inflammation and suggested that skin-resident
Tregs have a key role in maintaining immune homeostasis at
this site. Hence, it is conceivable that sterile cutaneous
inflammatory and autoimmune diseases might be associated
with impaired numbers or function of Tregs in lesional skin.
Atopic dermatitis (AD) is one of the most common
inflammatory skin diseases. Although the majority of studies
deciphering the pathophysiology of AD have focused on the
role of Th2 cells, more recent reports indicate the importance
of Tregs. When comparing the numbers of Tregs in peripheral
blood from AD patients and healthy donors, several groups
reported increased numbers of Tregs; moreover, Treg expan-
sion was positively associated with disease severity in AD
(Ou et al., 2004; Hijnen et al., 2009; Ito et al., 2009).
However, other studies revealed equal levels of Tregs in
peripheral blood from AD patients and healthy donors
(Brandt et al., 2009). Similar to the observations made in
peripheral blood, Treg numbers in lesional skin from AD
patients were found to be rather inconsistent. Whereas
Verhagen et al. (2006) did not detect Foxp3þ Tregs in skin,
Schnopp et al. (2007) have shown substantial numbers of
Tregs to be present in cutaneous lesions (Verhagen et al., 2006;
Schnopp et al., 2007). These contradictory results might be
explained by the different treatments of AD patients receive,
as some common AD treatments, such as cyclosporine,
glucocorticoids, and UV irradiation, are known to affect Treg
numbers (Brandt et al., 2009; Hijnen et al., 2009; Loser and
Beissert, 2009; Baumgrass et al., 2010; Stary et al., 2011).
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by the loss of immune tolerance to self,
leading to the activation and expansion of autoreactive
lymphocytes, as well as the production of autoantibodies
and immune complexes targeting multiple organs, includ-
ing the skin. It is generally accepted that the malfunction
of the immune system in SLE is based on a dysregulation
of T-cell tolerance. As at least in murine models of SLE
central tolerance mechanisms were unaffected, the break-
down of tolerance seems to emerge in the periphery, and
thus abnormalities in Treg numbers and/or function have
been suggested to contribute to T and B cell hyperreactivity.
Accordingly, most—but not all—studies revealed decreased
numbers of CD4þCD25hi Tregs in peripheral blood from SLE
patients; furthermore, the reduced Treg levels were found to
be inversely correlated with disease activity (Lee et al., 2006;
Mellor-Pita et al., 2006; Gerli et al., 2009; Buckner, 2010).
However, these results could not be confirmed when Foxp3
was used as a marker for Tregs, suggesting that in SLE patients
the expression of Foxp3 might be dissociated from the
CD4þCD25hi Treg phenotype (Lin et al., 2007; Bonelli et al.,
2008, 2009). Besides Treg numbers, the immunosuppressive
activity of Tregs has been studied intensively in SLE patients,
and several groups observed a defect in suppressor function,
which correlated with disease progression (Alvarado-Sanchez
et al., 2006; Venigalla et al., 2008; Miyara et al., 2009; Suen
et al., 2009), whereas others could not confirm such
functional deficiencies (Vargas-Rojas et al., 2008; Zhang
et al., 2008). These contradictory results might be explained
partially by the different methods used for Treg isolation and
quantification of suppressive activity. Moreover, the majority
of studies to assess Treg numbers and Treg function was
carried out in peripheral blood, whereas there is little or
almost no information on the aberration of Treg numbers and/
or function in lymphoid tissues or lesional skin. In SLE
patients, disease activity varies between phases of relative
remission and disease flares. Hence, it is conceivable that
Treg expansion might be similarly inconsistent. Recently,
Bonelli et al. (2009, 2010) identified a CD4þFoxp3þCD25
Treg subset with impaired suppressor function that was
specifically induced in phases of active disease in SLE
patients. Despite the large numbers of studies that have been
performed, the role of Tregs during SLE development and
progression remains elusive.
In psoriasis (an autoimmune-related chronic inflammatory
skin disease strongly associated with the activity of Th17 cells
and the Th17-driving cytokine IL-23), by contrast, Treg
function has been shown to be impaired (Sugiyama et al.,
2005; Nair et al., 2009). Recently, Bovenschen et al. (2011)
convincingly explained the underlying molecular mechanism
by demonstrating that in patients with severe psoriasis Tregs
can differentiate toward IL-17-expressing Tregs that contri-
bute to the perpetuation of autoimmunity. This conversion
was associated with the loss of Foxp3 expression, whereas
the levels of the Th17-specific transcription factor retinoic
acid-related orphan receptor gt (RORgt) were unchanged.
Notably, the cytokine IL-23, together with TCR stimulation,
induced the IL-17 secretion in Tregs and contributed to the
downregulation of Foxp3 (Bovenschen et al., 2011). As those
converted IL-17þ Tregs were enriched in lesional versus non-
lesional skin of psoriasis patients, a crucial role of Treg
conversion for psoriasis development and progression is
highly likely. Thus, the observations by Bovenschen et al.
add a new aspect to psoriasis research: the investigators
suggest a scenario in which, driven by the psoriatic cytokine
milieu, bona fide Foxp3þ Treg coexist in lesional skin with
IL-17þFoxp3RORgtþ Tregs that potentially become patho-
genic Th17 cells.
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